Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

BBSRC Supports Call for Multi-Disciplinary Research Centres in Synthetic Biology

Published: Friday, May 03, 2013
Last Updated: Friday, May 03, 2013
Bookmark and Share
Up to six centres will be funded in two phases; three in this financial year and three next financial year.

The call is expected to launch in June, preceded by an 'Expression of Interest' (EoI) stage to which interested parties must submit a short application. The 'Expression of Interest' stage will be launching early May.

Following the announcement of £600M capital investment for Research Councils in the autumn 2012 statement, a joint call will shortly be launched for multidisciplinary research centres in synthetic biology.

The call has been developed by the RCUK Synthetic Biology Working Group, and will be supported by BBSRC and EPSRC, with BBSRC administering the call.


BBSRC and EPSRC will announce a joint call for proposals in the coming months (anticipated June).

Up to six centres will be funded in two phases:
1.    Three in the 2013/14 financial year
2.    Three in the 2014/15 financial year

The full call will be preceded by an 'Expression of Interest' (EoI) stage where interested parties must submit a short application. The EoI (maximum 3 sides) will outline:

•    initial information about potential partners
•    scientific scope
•    management arrangements
•    funding demand (capital and recurrent)
•    institutional support

Potential applicants will be invited to a workshop hosted by the funders that will provide full details of the call, application and assessment procedures. The EoI will enable the funders to gauge interest in the call and to tailor the information workshop accordingly.

This preannouncement is to provide eligible investigators with additional time to consider the details of a proposal and to begin the process of identifying potential partners.

A further announcement with additional details will be published for the EoI.


Synthetic biology can be defined as 'the design and engineering of biologically based parts, novel devices and systems as well as the re-design of existing natural biological systems.'

In 2012, there were a number of important developments of direct relevance to synthetic biology research in the UK including:

•    the publication of 'A synthetic biology roadmap for the UK' which contained key recommendations to support and develop the UK research and industrial communities
•    the establishment of the Synthetic Biology Leadership Council (bringing together stakeholders from government, funding agencies, academia and industry)
•    the announcement of significant government investment in synthetic biology in the 2012 autumn statement

To implement the roadmap recommendations, deliver on the investment from government and taking heed of the advice from the Synthetic Biology Leadership Council, BBSRC and EPSRC, together with input from ESRC, MRC and the TSB, have come together to establish multidisciplinary research centres for synthetic biology, in partnership with relevant higher education institutions. This is part of a larger "Synthetic Biology for Growth Programme", which also includes provision for training cohorts of skilled researchers, enhancing the UK's gene synthesis capability and accelerating the route to market for innovative synthetic biology research.


The multidisciplinary Synthetic Biology Research Centres (SBRCs) will possess the vision, breadth of intellectual leadership and research resources required to integrate disciplines including bioscience, engineering, chemistry and IT into programmes of synthetic biology research of the highest international quality. They will also integrate the research activities of experimental scientists with those working on ethical, legal, societal and other issues within the context of responsible innovation.

The UK roadmap recognised that SBRCs are necessary to build on the UK's strong research foundations in order to create bioengineered solutions to underpin the UK bioeconomy.

The SBRCs will focus on strategic areas relevant to one or more key industrial sectors that could include:

•    fine and speciality chemicals
•    life science technologies
•    energy
•    environment
•    sensors (including diagnostics)
•    agriculture and food
•    medicines and healthcare

Once established the SBRCs, working with the Research Councils, will form a coordinated programme of investment providing 'one-stop' access to resources and expertise, enhancing developmental opportunities for academia and industry alike.

Aims and purpose

The UK synthetic biology roadmap recognised a need to establish SBRCs to boost the national research capacity and diversify UK expertise, stimulating innovation and facilitating interfaces with industry and other key stakeholders.

It is envisaged that there will be a two-phase call for proposals, one in 2013 and the second in 2014, each establishing up to three SBRCs. Each phase will have a total of £10M capital funding available and each centre would receive additional recurrent funding (up to £2M per annum for five years).

The purpose of the SBRC's is to:

•    develop and sustain a programme of internationally competitive synthetic biology research focused on strategic areas relevant to one or more industry sectors
•    provide a strong collaborative culture and supportive physical environment to attract excellent scientists and engineers in the collective endeavour of multidisciplinary research relevant to synthetic biology
•    drive advancement in modern research techniques to underpin synthetic biology
•    lead the development of new technologies and methodologies
•    provide the essential equipment and facilities required to enable adoption and uptake of synthetic biology approaches and, where appropriate, make this available to the wider community
•    recognising the specific purpose and position of the SBRC's, and avoiding overlaps with other funded initiatives, contribute to an overall synthetic biology UK network that acts to integrate the full breadth of UK synthetic biology and offers outreach and exchange opportunities for academia and industry alike
•    enhance the output of trained postdoctoral researchers and specialised technical staff

To achieve the above, the SBRCs will require:

•    a clear vision and strategy for undertaking world-class synthetic biology research
•    strong and empowered leadership and direction
•    robust project management
•    meaningful engagement with industry and understanding of sector needs
•    long-term support and commitment from the host institution(s) to space, research facilities and staff
•    a concentration of relevant research facilities to enable the cutting edge research
•    the necessary multidisciplinary blend of the best researchers
•    the capability and motivation to develop and advance new technologies and methodologies and meet the needs of the broader research community
•    a commitment to outreach, wider researcher engagement, and training
•    flexibility in the deployment of funds
•    adherence to current appropriate international standards and contribute to the further development of these

Each centre will need to demonstrate an awareness of other relevant activities, initiatives and groupings in the synthetic biology landscape. These include, but are not limited to, the forthcoming Innovation and Knowledge Centre (IKC) in Synthetic Biology, established research groups in academia and industry, the synthetic biology networks, the Synthetic Biology Leadership Council, the TSB Special Interest Group and others. They must consider how best to integrate with the other stakeholders in terms of sharing of information and resources, building on complementarities and exploiting synergies, whilst avoiding duplication of effort.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UK Bioscience Sparkles with New Diamond Fellowship
UK bioscience has received a major boost following the announcement of 16 new fellowships by the Biotechnology and Biological Sciences Research Council (BBSRC) including the first ever Diamond Fellowship, so named because the post will be based at the new Research Complex at Harwell, adjacent to the Diamond Light Source in Oxfordshire - the UK national synchrotron facility.
Tuesday, July 21, 2009
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos